ReNerve Limited has launched its Empliq tissue product range in the US, marking a strategic expansion into the growing dermal and amniotic tissue market. The launch complements its existing nerve repair portfolio and sets the stage for further growth.
- Launch of Empliq tissue range in the US
- First sales of Empliq Dermal deep-layer matrix product completed
- Amniotic and placental allograft products expected in Q3 CY25
- 53% revenue growth in FY25 driven by innovative nerve repair products
- Dermal and amniotic tissue market projected to exceed $3 billion by 2032
Strategic Product Launch
ReNerve Limited (ASX, RNV), a medical device company specialising in peripheral nerve injury repair, has officially launched its Empliq tissue product range in the United States. This launch follows the company’s first sales of the Empliq Dermal deep-layer matrix product, marking a significant commercial milestone. The Empliq range, developed in partnership with Berkeley Biologics, is designed to complement ReNerve’s existing nerve repair portfolio, targeting a suite of indications already familiar to the company.
The company plans to amplify its market presence with promotional activities at the upcoming American Society for Surgery of the Hand (ASSH) conference in Vancouver, scheduled for early October. This event will serve as a critical platform to engage surgeons and healthcare professionals with the new product offerings.
Market Opportunity and Product Pipeline
The Empliq range includes the recently launched dermal deep-layer matrix product, with amniotic and placental allograft products anticipated to reach the market in the third quarter of calendar year 2025. These products tap into the expanding dermal and amniotic tissue market, which is forecasted to grow from over $1.5 billion in 2026 to more than $3 billion by 2032.
ReNerve’s CEO, Dr Julian Chick, emphasised the strategic importance of this launch, highlighting the company’s commitment to providing surgeons with a broad suite of innovative solutions. The Empliq range is positioned to enhance the company’s existing offerings, which already include the FDA-cleared NervAlign® Nerve Cuff; a product that has demonstrated significant clinical success in reducing post-surgical pain for patients.
Financial Momentum and Growth Prospects
ReNerve reported a robust 53% revenue increase in fiscal year 2025, reaching $271,000 in sales. This growth underscores the market’s positive reception to its high-margin, scalable nerve repair products. The global nerve repair biomaterials market is projected to expand substantially, from an estimated $1.96 billion in 2024 to $6.2 billion by 2031, positioning ReNerve well for future growth.
With a comprehensive product portfolio that includes bioabsorbable nerve cuffs, deep dermal tissue products, amniotic tissue ranges, and next-generation nerve conduits and bionic nerve technologies, ReNerve is carving out a leadership position in the nerve repair space. The company’s focus on scientifically backed, ready-to-use solutions aims to improve surgical outcomes and patient quality of life worldwide.
Looking Ahead
As ReNerve rolls out the Empliq range and prepares for further product launches, the company is set to deepen its footprint in the US market and beyond. The upcoming ASSH conference will be a critical moment to gauge market traction and surgeon adoption. Investors and industry watchers will be keen to see how these new products perform commercially and how they integrate with ReNerve’s existing offerings to drive sustained growth.
Bottom Line?
Empliq’s launch marks a pivotal step for ReNerve, but market adoption and upcoming product rollouts will be key to sustaining momentum.
Questions in the middle?
- How quickly will surgeons adopt the new Empliq amniotic and placental products?
- What sales volumes and revenue impact can be expected from the Empliq range in FY26?
- How will ReNerve’s products compete against established players in the dermal and nerve repair markets?